AACAP Logo

Login  |  Donate  |  Help  |  About Us
57th Annual Meeting - October 26-31, 2010
2010 Research Forum

Perspectives on Current Pediatric Psychopharmacology Research Needs

Co-Chairs: Graham J. Emslie, M.D.; Christopher Kratochvil, M.D.

Tuesday, October 26
8:00a.m. – 5:00p.m.
(Separate Registration)
Sponsored by the Work Group on Research

Earn up to 7 CME Credits!!

Please note that attendance is limited so advanced registration is strongly recommended. The deadline for advanced registration ($100 USD) is September 15, 2010. After September 15, 2010 the cost is $150 USD.

If you have questions regarding the Research Forum, please contact Alyssa Sommer at 202.966.7300 ext. 157 or asommer@aacap.org.


The Research Forum is designed to drive the research policy agenda for child and adolescent psychiatry by creating an environment that encourages scientific exploration and collaboration of investigators across disciplines. The primary audience for the 2010 Research Forum is researchers, although others are invited to attend.


With the passage of the FDA Modernization Act, the Best Pharmaceuticals for Children Act, and the Pediatric Research Equity Act, we have seen vast increases in research for psychopharmacological treatments for youth with psychiatric disorders over the past decade. While our understanding of the efficacy and safety of available psychopharmacological treatments has expanded, we have only scratched the surface. Yet, funding for additional research on these medications is scarce. Research into new agents is important; however, we have many unanswered questions about the currently available medications we use daily to treat our youth's psychiatric illnesses. Sponsored by the Work Group on Research, the 2010 Research Forum was coordinated to identify the direction of future research on these available treatments.

The 2010 Research Forum consists of presentations that focus on the perspectives of various groups invested in future psychopharmacological research. Groups include: clinical researchers, pharmacoepidemiologists, clinicians, consumers, international researchers, and federal and funding agencies (FDA, NIH, and industry). Potential research methods to address the issues raised in the presentations will then be discussed. The Research Forum concludes with a discussion and audience participation to synthesize the overriding research questions that remain and potential solutions to conducting studies to answer these questions.

The 2010 Research Forum identifies research gaps with regard to currently available psychopharmacological agents in children and adolescents, and will identify future research priorities from the perspective of researchers, clinicians, consumers, and federal and funding agencies.

Clinical Researchers' Perspective

Stimulant Research: Strengths, Limitations, and Potential Targets
Christopher Kratochvil, M.D.

Pediatric Antidepressant Clinical Research : Past, Present, and Future
Moira Rynn, M.D.

Now and Later of Mood Stabilizers and Antipsychotics in Youth
Melissa DelBello, M.D.

Pharmacoepidemiologists' Perspective

Generating Pediatric Psychopharmacologic Research Needs from Community Patterns of Use
Julie Zito, Ph.D.

Clinicians' Perspective

Child Psychiatry Research: Equipping our Colleagues in the Trenches
Stephen Grcevich, M.D.

In the Trenches: A Pediatric Perspective on Gaps and Issues
Ruth Stein, M.D.

Consumers' Perspective

Child Psychopharmacology Research: What Do Families Want to Know?
Darcy Gruttadaro, J.D.

International Perspective

Transatlantic Differences in Dealing with the Gap of Evidence in New Generation Treatments
Jörg Fegert, M.D.

Federal and Funding Agency Perspectives

New Developments in Pediatric Psychopharmacology Research
Benedetto Vitiello, M.D.

Regulatory Issues in Child Psychiatry: Past, Present and Future
Mark Ritter, M.D., RPh.

Industry's Role in Child Psychopharmacology Research: Irrational Expectations vs. Reality-Based Limits
AJ Allen, M.D., Ph.D.

Perspective on Research Approaches

A Look at the Future of Comparative Effectiveness Research
John March, M.D., M.P.H.

Concluding Remarks

Andrés Martin, M.D., M.P.H.